Brookline Capital Management Forecasts CRSP FY2024 Earnings

CRISPR Therapeutics AG (NASDAQ:CRSP) – Investment analysts at Brookline Capital Management dropped their FY2024 earnings estimates for shares of CRISPR Therapeutics in a research note issued to investors on Tuesday, November 5th. Brookline Capital Management analyst L. Cann now anticipates that the company will post earnings per share of ($5.18) for the year, down from their previous forecast of ($4.88). The consensus estimate for CRISPR Therapeutics’ current full-year earnings is ($5.47) per share. Brookline Capital Management also issued estimates for CRISPR Therapeutics’ Q4 2024 earnings at ($1.36) EPS, FY2025 earnings at ($5.76) EPS, FY2026 earnings at $8.07 EPS, FY2027 earnings at $11.96 EPS and FY2028 earnings at $26.00 EPS.

A number of other equities analysts have also issued reports on the stock. Royal Bank of Canada reissued a “sector perform” rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research report on Wednesday. Cantor Fitzgerald reissued a “neutral” rating on shares of CRISPR Therapeutics in a report on Thursday, August 8th. Chardan Capital reduced their price target on CRISPR Therapeutics from $112.00 to $94.00 and set a “buy” rating for the company in a research report on Tuesday, August 6th. StockNews.com raised CRISPR Therapeutics to a “sell” rating in a report on Thursday. Finally, Truist Financial dropped their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. Three research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $74.94.

CRISPR Therapeutics Stock Down 0.5 %

Shares of NASDAQ:CRSP opened at $51.62 on Friday. CRISPR Therapeutics has a 52-week low of $43.42 and a 52-week high of $91.10. The stock has a market cap of $4.41 billion, a price-to-earnings ratio of -18.24 and a beta of 1.67. The business has a 50-day moving average price of $47.45 and a 200-day moving average price of $52.18.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. The firm had revenue of $0.60 million for the quarter, compared to the consensus estimate of $6.65 million. During the same period in the prior year, the firm earned ($1.41) EPS.

Insider Activity at CRISPR Therapeutics

In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the company’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the completion of the sale, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other CRISPR Therapeutics news, CEO Samarth Kulkarni sold 4,293 shares of the stock in a transaction dated Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $198,680.04. Following the completion of the transaction, the chief executive officer now owns 226,540 shares of the company’s stock, valued at $10,484,271.20. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of CRISPR Therapeutics stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total transaction of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares of the company’s stock, valued at $2,896,989.16. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in CRSP. Global Trust Asset Management LLC grew its stake in shares of CRISPR Therapeutics by 150.0% in the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company’s stock worth $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC grew its stake in CRISPR Therapeutics by 95.5% during the 2nd quarter. Larson Financial Group LLC now owns 565 shares of the company’s stock worth $31,000 after purchasing an additional 276 shares in the last quarter. GPS Wealth Strategies Group LLC increased its holdings in CRISPR Therapeutics by 99.7% during the 2nd quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company’s stock worth $33,000 after purchasing an additional 307 shares during the period. Itau Unibanco Holding S.A. acquired a new stake in CRISPR Therapeutics in the 2nd quarter valued at about $35,000. Finally, Orion Capital Management LLC boosted its stake in shares of CRISPR Therapeutics by 44.0% in the 1st quarter. Orion Capital Management LLC now owns 720 shares of the company’s stock valued at $49,000 after buying an additional 220 shares during the period. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.